CN104193809B - 一种凝血酶抑制及其制备方法、应用 - Google Patents
一种凝血酶抑制及其制备方法、应用 Download PDFInfo
- Publication number
- CN104193809B CN104193809B CN201410508635.2A CN201410508635A CN104193809B CN 104193809 B CN104193809 B CN 104193809B CN 201410508635 A CN201410508635 A CN 201410508635A CN 104193809 B CN104193809 B CN 104193809B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- thrombin
- relevant disease
- atherosclerosis
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000190 Thrombin Proteins 0.000 title claims abstract description 18
- 229960004072 thrombin Drugs 0.000 title claims abstract description 18
- 230000001629 suppression Effects 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 4
- 229920001184 polypeptide Polymers 0.000 claims abstract description 25
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 25
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 206010020772 Hypertension Diseases 0.000 claims abstract description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims abstract description 5
- 208000024806 Brain atrophy Diseases 0.000 claims abstract description 5
- 230000006793 arrhythmia Effects 0.000 claims abstract description 5
- 206010003119 arrhythmia Diseases 0.000 claims abstract description 5
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 5
- 206010008190 Cerebrovascular accident Diseases 0.000 claims abstract description 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims abstract description 4
- 208000006011 Stroke Diseases 0.000 claims abstract description 4
- 201000006370 kidney failure Diseases 0.000 claims abstract description 4
- 230000003143 atherosclerotic effect Effects 0.000 abstract description 6
- 230000002265 prevention Effects 0.000 abstract description 5
- 239000002671 adjuvant Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 231100000915 pathological change Toxicity 0.000 abstract description 3
- 230000036285 pathological change Effects 0.000 abstract description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 abstract description 2
- 108091006905 Human Serum Albumin Proteins 0.000 abstract description 2
- 102000008100 Human Serum Albumin Human genes 0.000 abstract description 2
- 239000002202 Polyethylene glycol Substances 0.000 abstract description 2
- 239000003146 anticoagulant agent Substances 0.000 abstract description 2
- 229940127219 anticoagulant drug Drugs 0.000 abstract description 2
- 229940098773 bovine serum albumin Drugs 0.000 abstract description 2
- 239000002775 capsule Substances 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 238000001990 intravenous administration Methods 0.000 abstract description 2
- 238000010253 intravenous injection Methods 0.000 abstract description 2
- 239000007922 nasal spray Substances 0.000 abstract description 2
- 229940097496 nasal spray Drugs 0.000 abstract description 2
- 239000006187 pill Substances 0.000 abstract description 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 210000000709 aorta Anatomy 0.000 description 7
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
- 108010028554 LDL Cholesterol Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 201000001962 aortic atherosclerosis Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003868 thrombin inhibitor Substances 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- CXZFXHGJJPVUJE-CIUDSAMLSA-N Ala-Cys-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)O)N CXZFXHGJJPVUJE-CIUDSAMLSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010065558 Aortic arteriosclerosis Diseases 0.000 description 1
- MCYJBCKCAPERSE-FXQIFTODSA-N Arg-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N MCYJBCKCAPERSE-FXQIFTODSA-N 0.000 description 1
- ZJBUILVYSXQNSW-YTWAJWBKSA-N Arg-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O ZJBUILVYSXQNSW-YTWAJWBKSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- GRNOCLDFUNCIDW-ACZMJKKPSA-N Cys-Ala-Glu Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CS)N GRNOCLDFUNCIDW-ACZMJKKPSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 1
- HZISRJBYZAODRV-XQXXSGGOSA-N Glu-Thr-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O HZISRJBYZAODRV-XQXXSGGOSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
- 206010065560 Mesenteric arteriosclerosis Diseases 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 description 1
- 206010038378 Renal artery stenosis Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- -1 TC) Chemical compound 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 210000003017 ductus arteriosus Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410508635.2A CN104193809B (zh) | 2014-09-28 | 2014-09-28 | 一种凝血酶抑制及其制备方法、应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410508635.2A CN104193809B (zh) | 2014-09-28 | 2014-09-28 | 一种凝血酶抑制及其制备方法、应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104193809A CN104193809A (zh) | 2014-12-10 |
CN104193809B true CN104193809B (zh) | 2016-08-17 |
Family
ID=52079205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410508635.2A Active CN104193809B (zh) | 2014-09-28 | 2014-09-28 | 一种凝血酶抑制及其制备方法、应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104193809B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2886576T3 (es) * | 2015-08-05 | 2021-12-20 | Shaanxi Micot Tech Limited Company | Compuesto de múltiples dianas con actividad anticoagulante y antiplaquetaria, método de preparación para el mismo y uso del mismo |
CN105175505A (zh) * | 2015-09-08 | 2015-12-23 | 苏州普罗达生物科技有限公司 | 瘦素激动多肽及其应用 |
CN105175504A (zh) * | 2015-09-08 | 2015-12-23 | 苏州普罗达生物科技有限公司 | 血管性血友病因子抑制多肽及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1050720A (zh) * | 1989-10-03 | 1991-04-17 | 默里尔多药物公司 | 抗凝血肽 |
US5356875A (en) * | 1991-02-28 | 1994-10-18 | Farmitalia Carlo Erba S.R.L. | Anti-thrombin polypeptides and pharmaceutical compositions thereof |
-
2014
- 2014-09-28 CN CN201410508635.2A patent/CN104193809B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1050720A (zh) * | 1989-10-03 | 1991-04-17 | 默里尔多药物公司 | 抗凝血肽 |
US5356875A (en) * | 1991-02-28 | 1994-10-18 | Farmitalia Carlo Erba S.R.L. | Anti-thrombin polypeptides and pharmaceutical compositions thereof |
Non-Patent Citations (2)
Title |
---|
A novel class of small functional peptides that bind and inhibit human α-thrombin isolated by mRNA display;Nikolai A Raffler et al.;《Chemistry & Biology》;20030131;第10卷(第1期);69-79 * |
凝血酶抑制肽研究进展;王子伟等;《粮食与油脂》;20140310;第27卷(第3期);第4-6页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104193809A (zh) | 2014-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Savelieva et al. | Update on atrial fibrillation: part I | |
JP5926279B2 (ja) | Dpp−4阻害剤 | |
CN104193807B (zh) | 凝血酶抑制多肽及其制备方法、应用 | |
CN104193809B (zh) | 一种凝血酶抑制及其制备方法、应用 | |
CN104736552B (zh) | 用于预防或治疗心血管疾病的、包含对血管紧张素‑i转换酶表现出抑制活性的肽作为活性成分的药物组合物 | |
CN105339010A (zh) | 使用因子xii抑制剂和c1-抑制剂的联合疗法 | |
US20040081619A1 (en) | Method of prophylaxis against large myocardial infarctions | |
Xie et al. | The function of the ACE2/Ang (1-7)/Mas receptor axis of the renin-angiotensin system in myocardial ischemia reperfusion injury. | |
WO2001077673A1 (en) | Hypotensors | |
CN105175504A (zh) | 血管性血友病因子抑制多肽及其应用 | |
JP2002088098A (ja) | アコヤ貝由来のace阻害ペプチド | |
WO2007088681A1 (ja) | グレリン産生促進剤 | |
Brown | " Enterogastrone" and other new gut peptides | |
CN105175503A (zh) | 因子viii抑制多肽及其应用 | |
CN109562149A (zh) | C1酯酶抑制剂的药物制剂 | |
CN105175505A (zh) | 瘦素激动多肽及其应用 | |
EP1467801A1 (en) | Method of prophylaxis against large myocardial infarctions | |
JP2008208096A (ja) | クラゲタンパク質由来の新規ペプチドとその用途 | |
WO2014030977A1 (ko) | 안지오텐신-i 전환 효소 저해능을 나타내는 펩타이드를 유효성분으로 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물 | |
JP2006265241A (ja) | クラゲタンパク質由来の新規ペプチドとその用途 | |
JP4242728B2 (ja) | 新規生理活性ペプチド及びその用途 | |
CN105131088A (zh) | 一种雪莲果蛋白多肽及其应用 | |
JP4263892B2 (ja) | アンジオテンシン変換酵素阻害剤含有組成物の製造方法 | |
JP3992143B2 (ja) | 新規生理活性ペプチド | |
Lakoumentas et al. | Cholesterol levels and the benefit of statins in heart failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhou Ailing Inventor after: Song Mingmei Inventor after: Sha Jie Inventor before: Luo Ruixue |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160718 Address after: 266000 Licang, Qingdao, No. nine East water road, No. 320, No. Applicant after: Gu Yukui Address before: 215000 Jiangsu City, Suzhou hi tech Zone Jinfeng Road, building 8, No. 15 Applicant before: Suzhou Pu Luo Da Biotechnology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhou Ailing Inventor after: Song Mingmei Inventor after: Sha Jie Inventor after: Song Yuli Inventor after: Du Wenchao Inventor before: Zhou Ailing Inventor before: Song Mingmei Inventor before: Sha Jie |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170503 Address after: 518000 Shenzhen, Nanshan District Province, a high tech in the middle of the road No. ten Shenzhen biological incubation base, building 212, room 2, No. Patentee after: Shenzhen Union Medical Biotechnology Co., Ltd. Address before: 266000 Licang, Qingdao, No. nine East water road, No. 320, No. Patentee before: Gu Yukui |
|
TR01 | Transfer of patent right |